CLC Number:
| [1] Schmidt-Wolf I G, Leftova P, Johnston V. Propagation of large number of T cells with natural killer cell makers[J]. Br J Haematol, 1994, 87(3):453-458. [2] Finke S, Trojaneck B, Lefterova P, et al. Increase of proliferation rate and enhancement of antitumor cytoxicity of expanded human CD3+CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene[J]. Gene Ther, 1988, 5(1):31-39. [3] Zoll B, Lefterova P, Ebert O. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation[J]. Cytokine, 2000, 12 (92):1385-1390. [4] 王志华. 细胞因子诱导的杀伤细胞治疗癌症的基础与临床[J]. 中国医药导报, 2013, 10(7):4-8. [5] Ortaldo J R, Winkler-Pickett R T, Yagita H, et al.Comparative studies of CD3- and CD3+CD56+ cell:examination of morphology, function, T cell receptor rearrangement, and pore-forming protein expression[J]. Cell Immunol, 1991, 136(2):486-495. [6] 要跟东，霍红旗，李鹏，等. 健康人和胃癌患者组织中CIK细胞抗肿瘤作用的观察[J]. 中华肿瘤防治杂志，2011,18(4):272-274. [7] Carlens S, Gilljam M, Chambers B J, et al. A new method for in vitro expansion of cytotoxic human CD3+CD56+ natural killer cells[J]. Hum Immunol, 2001, 62(10):1092-1098. [8] Sangiolo D. Cytokine induced killer cell as promising immunotherapy for solid tumors[J]. J Cancer, 2011, 2:363-368. [9] 张凤鸣, 王小沛, 宋玉琴, 等. 冻存外周血干细胞扩增CIK细胞及其体外的抗肿瘤效应[J]. 中华肿瘤防治杂志, 2010, 17(15):1206-1209. [10] 童春容, 耿彦彪, 江倩, 等. 自体细胞因子诱导的杀伤细胞治疗白血病合并丙型病毒性肝炎的首次报告[J]. 北京医科大学学报, 2000, 32(3):251-255. [11] 张冰, 施明, 谢云波, 等. 慢性丙型肝炎患者CIK细胞的诱导培养及细胞亚群分析[J]. 肝脏, 2012, 17(5):311-314. [12] 凌世淦. 丙型肝炎研究的挑战与希望[J]. 中华微生物学与免疫学杂志, 2004, 24(11):921-922. [13] Kaplan D E, Sugimoto K, Newton K, et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell response in acute hepatitis C[J]. Gastroenterology, 2007, 132:654-666. [14] Rchermann B. Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection[J]. Nat Rev Immunol, 2005, 5:215-229. [15] Nakamura H, Uyama H, Enomoto H, et al. The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C[J]. Hepatogastroenterology, 2003, 50(49):222-226. [16] De Francesco R, Carff A. Advance in the development of new therapeutic angents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus[J]. Adv Drug Deliv Rev, 2007, 59(12):1242-1262. [17] 邓涛, 陈乃玲, 陈天宝, 等. 丙肝病毒(HCV)基因免疫实验研究[J]. 中国免疫学杂志, 1999, 15(11):494-496. [18] 鲍峰, 徐岩, 尹富华, 等. CIK细胞过继免疫治疗中晚期恶性肿瘤的临床研究[J]. 辽宁医学杂志, 2003, 17(4):187-188. [19] Schmidt-Wolf G D, Negrin R S, Schmidt-Wolf I G. Activated T cells and cytokine-induced CD3+CD56+ killer cells[J]. Ann Hematol, 1997, 74(2):51-56. [20] Frese M, Schwarzle V, Barth K, et al. Interferon-gamma inhibits relication of subgenomic and genomic hepatitis C virus RNAs[J]. Hepatology, 2002, 35:694-703. [21] 王志华, 吴少雄, 吕玉瑛, 等. 应用CIK细胞静脉输注治疗癌症的临床护理[J]. 中国医药科学, 2012, 2(17):52-53. |
| No related articles found! |
|
||
